Regulatory

Isofol appoints nomination committee ahead of the Annual General Meeting 2025

By

GOTHENBURG, Sweden, November 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that the members of the nomination committee for the Annual General Meeting 2025 have been appointed in accordance with the principles for appointing nomination committees that were adopted at the Annual General Meeting 2024. The information […]

Isofol appoints nomination committee ahead of the Annual General Meeting 2025 Read More »

Isofol Medical AB (publ) publishes interim report, January–September 2024

By

GOTHENBURG, Sweden, November 12, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–September 2024 is now available, in Swedish, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. Third quarter, July–September 2024 Net revenue amounted to kSEK 0 (0) and

Isofol Medical AB (publ) publishes interim report, January–September 2024 Read More »

Isofol strengthens the outlook for further extending the patent protection of its drug candidate arfolitixorin

By

GOTHENBURG, Sweden, September 17, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces positive outcomes of a preliminary patentability report on a new international product patent application for arfolitixorin, submitted under the PCT (Patent Cooperation Treaty). If granted, the patent could significantly strengthen and prolong arfolitixorin’s intellectual property protection internationally. The information in

Isofol strengthens the outlook for further extending the patent protection of its drug candidate arfolitixorin Read More »

Isofol Medical AB (publ) publishes interim report, January–June 2024

By

GOTHENBURG, Sweden, August 21, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–June 2024 is now available, in Swedish, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. Second quarter, April–June 2024 Net revenue amounted to kSEK 0 (0) and

Isofol Medical AB (publ) publishes interim report, January–June 2024 Read More »

Isofol appoints Margareta Hagman as new Chief Financial Officer

By

GOTHENBURG, Sweden, July 30, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announced today that the company has appointed Margareta Hagman as the new Chief Financial Officer. She has extensive financial experience from biotech and pharmaceutical companies and will assume the position on August 13. The information in the press release is intended for

Isofol appoints Margareta Hagman as new Chief Financial Officer Read More »

Isofol announces new preclinical data supporting the previously communicated clinical development plan for arfolitixorin

By

GOTHENBURG, Sweden, July 16, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces results from two preclinical studies that support the dose-response relationship for arfolitixorin. These positive data further strengthen the hypothesis behind the design of the clinical Phase Ib/II study in patients with colorectal cancer that Isofol plans to conduct in collaboration

Isofol announces new preclinical data supporting the previously communicated clinical development plan for arfolitixorin Read More »

Isofol announces a post hoc per-protocol analysis of the AGENT study, further supporting arfolitixorin’s continued clinical development

By

GOTHENBURG, Sweden, July 5, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that an external committee of experts has performed a post hoc per-protocol analysis of the clinical phase III study AGENT that shows new results in favor of arfolitixorin. These positive data, together with conclusions from earlier studies and analyses, strengthen

Isofol announces a post hoc per-protocol analysis of the AGENT study, further supporting arfolitixorin’s continued clinical development Read More »

Isofol and Charité sign collaboration agreement on further clinical development of arfolitixorin

By

GOTHENBURG, Sweden, May 24, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company has signed a collaboration agreement with the world-leading academic hospital Charité Universitätsmedizin in Berlin, and Professor Sebastian Stintzing, for the further clinical development of arfolitixorin. The collaboration includes strategic planning of the clinical development of arfolitixorin in

Isofol and Charité sign collaboration agreement on further clinical development of arfolitixorin Read More »

Scroll to Top